Answers are grounded in this paper and cite their sources.
Chronic hyperglycaemia in type 2 diabetes drives a self-perpetuating cycle of glucotoxicity. This study investigated the therapeutic potential of extracts from the green seaweed Chaetomorpha linum (O.F.Müller) Kützing, 1845 to mitigate glucotoxicity in rats adipocytes. Liquid chromatography-mass spectrometry (LC-MS) analysis revealed distinct phytochemical profiles, with the aqueous extract containing isolobinine, kurarinol, rutaevin, and proanthocyanidin-A2, and the ethanol extract containing caryoptin, mesembrinol, 12-deoxyphorbol-13-octadecanoate, and aspulvinone H. Bioactivity assays showed that C. linum extracts reversed glucotoxicity-induced pathologies, restoring glucose uptake (3.9–6.1 mg/g adipose tissue at 240 µg/mL), suppressing polyol pathway enzyme activities (2.7–9.5 µmol/min/mg, at 240 µg/mL), and enhancing antioxidant defense markers. Concurrently, the extracts inhibited key digestive enzymes (26.7–41.0 µmol/min/µL, at 240 µg/mL). Molecular docking supported these findings, with rutaevin showing the high affinity for aldose reductase (−11.7 kcal/mol) and proanthocyanidin-A2 for lipase (−9.9 kcal/mol) and glutathione peroxidase (−7 kcal/mol). These findings highlight C. linum as a promising source of bioactive compounds for diabetes management.
No takes yet. Share an insight, caveat, or question.
Magwaza et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: